As more men compare convenient online ED treatment options in 2026, this MEDVi QUAD review examines the newly updated sildenafil, tadalafil, PT-141, and L-citrulline formula, why the change may appeal to patients seeking a broader compounded approach, and what to verify with a licensed provider before enrolling.
NEWARK, DE / ACCESS Newswire / July 18, 2026 / This content is promotional in nature and is intended for consumer education regarding a commercially available product. It's a paid advertorial - a commission is earned if you use the links in this article. Product claims come from the brand, not from this publication. MEDVi QUAD is a compounded prescription product: it's available only after a licensed provider evaluates you, and approval isn't guaranteed. It's not FDA-approved; compounded medications aren't reviewed by the FDA for safety, effectiveness, or quality before reaching patients. Official site: https://quad.medvi.org/. Details here reflect brand materials and a direct brand communication reviewed in July 2026 - confirm anything that matters to you before enrolling.
MEDVi QUAD Reviews 2026: Could This New PT-141 4-in-1 Formula Be the ED Treatment Upgrade Men Have Been Looking For? (Consumer Research)
TL;DR: MEDVi has updated the QUAD™ formula. Per a direct communication from MEDVi to this publication, PT-141 and L-Citrulline have replaced Vardenafil and Apomorphine. The current formula, confirmed on MEDVi's live product page as of July 2026, is sildenafil, tadalafil, PT-141, and L-Citrulline. Some earlier online coverage of MEDVi QUAD - including prior coverage on this platform - describes the previous formula and has not been updated to reflect this change. This article covers what changed, why it matters, and what to verify before enrolling.
You saw an ad for MEDVi QUAD - or you already knew the brand and came back because something about the ingredient list didn't match what you remembered. Good instinct either way. MEDVi just updated the formula, and if you're reading this, you're finding out before almost anyone else. Here's exactly what changed, straight from MEDVi to this publication and confirmed on the brand's own page.
QUAD is offered through three separate entities, and that structure hasn't changed with the formula update:
Platform: MEDVi, LLC (131 Continental Dr, Ste 305, Newark, DE 19713) - doesn't prescribe, isn't a pharmacy
Licensed medical group: CareGLP Affiliated P.C.s and OpenLoop Health - makes all prescribing decisions independently
Compounding pharmacy: Belmar Pharma Solutions - compounds and dispenses the prescription
Prescription medication is available only after consultation and approval by a licensed healthcare provider, if clinically appropriate - approval is not guaranteed.
Start the MEDVi QUAD provider consultation process
MEDVi QUAD Quick Facts: What Changed
Brand: MEDVi
Program: QUAD™
What changed: Vardenafil and apomorphine replaced with PT-141 and L-Citrulline
Unchanged ingredients: Sildenafil, tadalafil
Source of update: Direct communication from MEDVi to this publication, confirmed on MEDVi's live product page
As of: July 2026
Current promotional price: $114/month (brand-stated)
Program type: Telehealth compounded prescription - not sold over the counter
MEDVi QUAD Ingredients 2026: PT-141 and L-Citrulline Replace Vardenafil and Apomorphine
Quick answer: MEDVi QUAD's current formula, confirmed in July 2026, is sildenafil, tadalafil, PT-141, and L-Citrulline. This replaces the prior formula of sildenafil, tadalafil, vardenafil, and apomorphine. MEDVi communicated the change directly to this publication; the update is also reflected on the brand's live product page.
Per a communication from MEDVi to this publication, the QUAD formula has been updated. Vardenafil and Apomorphine are gone. PT-141 and L-Citrulline replace them. Sildenafil and Tadalafil remain unchanged. MEDVi's live product page, reviewed in July 2026, currently lists the updated four-ingredient formula, which is consistent with that communication.
Previous formula (being phased out): Apomorphine, Vardenafil, Sildenafil, Tadalafil
Current formula (as of July 2026): PT-141, L-Citrulline, Sildenafil, Tadalafil
Two of the four ingredients changed; two stayed the same. If you're comparing this article against older MEDVi QUAD coverage - including prior pieces on this platform - that's the reason for the discrepancy. Older coverage was accurate for the formula that existed at the time it was published; it has not been retroactively updated to reflect this change, and readers relying on it should treat the ingredient list here as the current one.
Buyer takeaway: If you've read anything about MEDVi QUAD before today, check the ingredient list against this one before you enroll - two of the four active ingredients have changed.
Check the current QUAD ingredient list on MEDVi's official page
Why the Change Is Worth Understanding, Not Just Noting
This isn't a cosmetic label update - the two ingredients removed and the two added work differently, and it's worth understanding both sides before assuming the change is purely additive.
Apomorphine, which is being removed, is FDA-approved for Parkinson's disease and was used in the prior QUAD formula for an off-label purpose. Vardenafil, also removed, is a PDE5 inhibitor in the same drug class as sildenafil and tadalafil - meaning the prior formula combined three PDE5 inhibitors plus apomorphine in a single dose.
PT-141 (bremelanotide), the new addition, is FDA-approved as a standalone product for a different indication in a different patient population, and its use here is off-label. L-Citrulline, the other addition, is a naturally occurring amino acid; ingredient-level research on it centers on nitric oxide-related exercise and cardiovascular outcomes rather than ED specifically.
The net effect: the updated formula still combines two PDE5 inhibitors (sildenafil and tadalafil) with PT-141, which is a real change in composition but not a change in the core consideration that matters most for a prescriber's review - that sildenafil and tadalafil together are not the typical way ED medications are prescribed, and combination use is not standard first-line practice. That consideration applied to the old formula and applies to the current one. It's a question for your prescriber, not something this article - or MEDVi's marketing - resolves. Individual response to any of these ingredients, alone or combined, varies by patient and is not something this article can predict.
Buyer takeaway: Removing apomorphine and vardenafil and adding PT-141 (bremelanotide) and L-Citrulline is a real formula change, not a relabeling - but it doesn't remove the two-PDE5-inhibitor combination that matters most to a prescriber's review.
What to Ask Your Prescriber Before Starting
Because the current formula still combines two PDE5 inhibitors, this is a conversation for your prescriber, not something to assess from an ad or a formula-comparison article. PDE5 inhibitors as a class carry cardiovascular considerations, including interactions with nitrate medications, and combining two of them is not standard first-line practice for ED. Tell your prescriber about every medication and supplement you take, any history of low blood pressure, heart conditions, or nitrate use, and ask specifically why this combination - old formula or new - is being recommended for you rather than a single-agent option. A licensed provider evaluating your individual health history is who should make that call, not brand copy describing the update.
Buyer takeaway: Bring your full medication and health history to the consultation regardless of which formula version you've read about - the prescriber's review matters more than the ingredient label, and individual results and tolerability vary from patient to patient.
Begin your MEDVi QUAD provider evaluation
Current QUAD Pricing
Per MEDVi's live product page reviewed in July 2026, promotional pricing starts at $114 per month, with $179 per month shown as a reference price, and free rush shipping included. Earlier coverage of the prior formula listed a $119 promotional starting price - a small change that's worth noting alongside the ingredient update, since both reflect the same source (MEDVi's live page) at different points in time. Per the brand, this price is stated to include the physician consultation, medication, and shipping. Pricing is subject to change - confirm current figures on the official site before enrolling.
Buyer takeaway: The promotional price moved along with the ingredients - confirm today's exact figure at checkout rather than relying on any previously published number, including the $119 figure in earlier coverage.
View current MEDVi QUAD pricing and what's included
Cancellation and Refund Terms
Per MEDVi's published Subscription Services Cancellation and Refund Policy - linked from MEDVi's own site and unrelated to the ingredient update - cancellation requests must be received at least 72 hours before the next billing date to prevent the next charge; missing that window means the next cycle is billed before cancellation takes effect. Other than cancellation due to medical disqualification by the provider, no refund is issued upon cancellation, and federal law generally prohibits returning prescription medications once dispensed. These terms are unchanged by the formula update and apply to enrollment under the current formula the same way they applied under the prior one.
Buyer takeaway: Set a cancellation reminder for at least 72 hours before your billing date - that rule doesn't reset or change with the new ingredient list.
See MEDVi QUAD's current subscription terms
A Note on Prior Coverage and This Update
MEDVi's communication about this formula change was issued to all approved partners, and it applies to every piece of existing QUAD coverage, not just one placement. Prior coverage of MEDVi QUAD - including earlier placements describing the three-entity telehealth structure, the 72-hour cancellation rule, the FDA regulatory context around MEDVi's broader business, and the platform's enrollment process - remains accurate on those points, which the formula change does not affect. Where that earlier coverage lists apomorphine and vardenafil as active ingredients, that reflected the formula in place at the time each piece was published. Those articles were accurate when written and have not been retroactively edited; this article's ingredient list - PT-141, L-Citrulline, sildenafil, tadalafil - is the current one as of July 2026, confirmed directly by MEDVi and cross-checked against the brand's live page.
Readers who want the fuller verification framework - the three-entity structure in detail, the complete cancellation and refund breakdown, a branded-medication comparison, and a full legitimacy checklist - can review prior verification coverage of MEDVi QUAD's original formula, cancellation terms, and regulatory context, published before this update. That coverage's ingredient list is now superseded by this article; its other verification points are unaffected by the formula change.
Regulatory Context: What the FDA Warning Letter Does and Doesn't Cover
Quick answer: Is MEDVi QUAD's new formula FDA-approved? No. Neither the current formula (PT-141, L-Citrulline, sildenafil, tadalafil) nor the prior one is FDA-approved as a compounded combination. A separate February 2026 FDA warning letter to MEDVi concerned GLP-1 products only, not QUAD.
MEDVi, LLC received an FDA warning letter (#721455) dated February 20, 2026, concerning website claims about compounded semaglutide and tirzepatide - MEDVi's GLP-1 weight-loss products. The letter did not reference QUAD, and QUAD involves an entirely different set of ingredients and a different health category. An FDA warning letter is not a product ban, a court judgment, or a finding that a specific product is unsafe - it's a formal notice giving a company the opportunity to respond and correct the identified issues. Readers who want the full regulatory picture - the warning letter itself, related media coverage of MEDVi's broader business, and pending litigation involving a clinical infrastructure partner - can review a dedicated regulatory breakdown covering the FDA warning letter and why it doesn't involve QUAD. MEDVi's support channels can address current status directly.
Buyer takeaway: The FDA warning letter is real but unrelated to QUAD or to this formula update - don't let it stand in for verifying the ingredient-specific facts that do apply here.
Learn more about MEDVi QUAD's current program status
Things to Verify Before You Enroll
Verify 1 - Current formula at checkout: confirm the ingredient list shown at your specific checkout matches PT-141, L-Citrulline, sildenafil, and tadalafil, since brand pages and pricing can vary by promotion.
Verify 2 - Your eligibility: approval depends on your consultation with the licensed medical group; enrolling does not guarantee it.
Verify 3 - Current pricing: promotional pricing may change; confirm the current rate on the official site.
Verify 4 - Cancellation timing: the 72-hour pre-billing notice requirement applies regardless of formula version.
Verify 5 - Insurance: insurance coverage, if any, depends on your specific plan and is not confirmed by this article.
Confirm your eligibility with MEDVi's intake process
Fast Facts
Brand: MEDVi
Program: QUAD™ by MEDVi
Formula update source: direct MEDVi communication to this publication, confirmed on MEDVi's live page, July 2026
Current ingredients: Sildenafil, Tadalafil, PT-141, L-Citrulline
Previous ingredients (superseded): Sildenafil, Tadalafil, Vardenafil, Apomorphine
Platform entity: MEDVi, LLC - Newark, DE
Licensed medical group: CareGLP Affiliated P.C.s / OpenLoop Health
Compounding pharmacy: Belmar Pharma Solutions
Current promotional price: $114/month (brand-stated, July 2026)
Standard price: $179/month (brand-stated reference price)
Cancellation notice: 72 hours before billing date
Refund: medical disqualification only; no other refunds per policy
Frequently Asked Questions
What exactly changed in the MEDVi QUAD formula?
Per MEDVi's communication to this publication, Vardenafil and Apomorphine have been removed and replaced with PT-141 and L-Citrulline. Sildenafil and Tadalafil are unchanged. The current formula is sildenafil, tadalafil, PT-141, and L-Citrulline.
Why does older MEDVi QUAD coverage list different ingredients?
Earlier coverage, including prior placements on this platform, was accurate for the formula in place when it was published. It has not been retroactively updated. This article reflects the current formula as of July 2026.
Is the updated formula safer than the previous one?
That's a clinical determination for a prescriber, not a comparison this article makes. The updated formula still combines two PDE5 inhibitors (sildenafil and tadalafil), which carries the same class-level considerations as before. Discuss your full medical history with your prescriber regardless of which formula version is being discussed.
Did the price change along with the formula?
Yes, slightly. Earlier coverage listed a $119 promotional starting price; MEDVi's current page lists $114. Both figures come from MEDVi's live product page at different points in time. Confirm the current price directly before enrolling.
Does the formula update affect the cancellation or refund policy?
No. MEDVi's Subscription Services Cancellation and Refund Policy - including the 72-hour notice requirement and the medical-disqualification-only refund rule - is unrelated to the ingredient formula and applies the same way under the current formula as it did previously.
Is MEDVi QUAD FDA-approved?
No. Compounded medications, including QUAD in either formula version, are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
See MEDVi's compounded-medication disclosures and current formula
What is PT-141?
PT-141 is a common name for bremelanotide, a compound that acts on melanocortin receptor pathways in the central nervous system. It's FDA-approved as a standalone product for a different indication in a different patient population; its use in MEDVi QUAD's compounded formula is off-label. This publication does not independently verify how PT-141 performs within the specific compounded combination MEDVi dispenses.
What is bremelanotide?
Bremelanotide is the generic name for PT-141. The two terms refer to the same compound; MEDVi's marketing materials and product page use "PT-141," while bremelanotide is the term used in its FDA-approved standalone product's labeling and in clinical literature.
What is L-Citrulline used for?
L-Citrulline is a naturally occurring amino acid studied primarily as a nitric oxide precursor, with ingredient-level research focused on exercise performance and cardiovascular outcomes rather than ED specifically. Its role in MEDVi QUAD's compounded formula is brand-described; this publication has not independently evaluated its contribution to the finished combination.
Is L-Citrulline a prescription ingredient?
L-Citrulline itself is an amino acid available outside prescription channels, but in MEDVi QUAD it's compounded into a prescription formulation alongside sildenafil, tadalafil, and PT-141, and is dispensed only through the prescription pathway described in this article - not sold or evaluated here as a standalone supplement.
Does MEDVi QUAD still contain apomorphine?
No. Per MEDVi's communication to this publication and the brand's current live page, apomorphine has been removed from the QUAD formula and replaced with PT-141 and L-Citrulline. Coverage describing apomorphine as a current ingredient reflects the prior formula version.
Is vardenafil still in MEDVi QUAD?
No. Vardenafil has been removed from the current formula. The updated formula retains sildenafil and tadalafil and adds PT-141 and L-Citrulline in place of vardenafil and apomorphine.
Review the current MEDVi QUAD program page
The Bottom Line
MEDVi updated the QUAD formula. Vardenafil and Apomorphine are out; PT-141 and L-Citrulline are in, alongside the unchanged sildenafil and tadalafil. That's confirmed directly by MEDVi and by the brand's current live page. If you've seen QUAD described elsewhere with the older ingredient list, that's not an error - it's just not current. The program's structure hasn't changed: three separate entities, physician-gated prescribing, a 72-hour cancellation window. What has changed is what's actually in the dose. If you're considering QUAD, the next step is the same as it's always been - a consultation with MEDVi's affiliated medical group, where a licensed provider evaluates whether the current formula is right for you. Visit the official MEDVi QUAD site for current program details before making a decision.
MEDVi Contact Information
Company: MEDVi, LLC
Address: 131 Continental Dr, Ste 305, Newark, DE 19713
Email (QUAD product page): hello@medvi.org
Phone (QUAD product page): 24/7 patient support line
Official site: https://quad.medvi.org/
Note: MEDVi's general policy pages list a different support phone number than the QUAD product page above. Contact MEDVi directly to confirm the right channel for your specific question.
Disclosure and Compliance Information
Material Limitations: The formula-change claim in this article is based on a direct communication from MEDVi to this publication - issued to all approved partners and applicable to prior QUAD coverage generally, not a single placement - cross-checked against MEDVi's official product page as reviewed in July 2026. This was not an independently located dated public announcement from the brand. No product testing was conducted by this publication. MEDVi's contact channels show a discrepancy between the QUAD product page (hello@medvi.org) and MEDVi's general policy pages (a different phone number); this article uses the QUAD-specific contact page as primary. MEDVi's Terms of Service identify the operating entity as "MEDVi, LLC," while the site's footer copyright notice separately reads "MEDVi, Inc."; this article uses "MEDVi, LLC" per the Terms of Service as the primary entity of record. Guarantee/refund terms beyond the published cancellation policy were not further verified. Contact MEDVi directly to verify any material claim before enrolling.
Results Disclaimer: Individual response to any medication or ingredient discussed in this article, including under either formula version, varies by patient. No outcome is guaranteed, and nothing in this article should be read as a prediction of individual results.
Third-Party Feedback Platforms: This article does not endorse the accuracy of any third-party review platform. Evaluate any third-party reviews critically and independently.
Forward-Looking Statements: This article reflects brand materials and direct brand communication reviewed in July 2026. Formula, pricing, and program policies may change without notice. Rely on MEDVi's official site for current information.
Marketing Language Notice: Attribution language throughout this article identifies claims as brand-stated. Any promotional phrasing associated with QUAD reflects MEDVi's own marketing language and is not an independent ranking, endorsement, or lab-verified claim by this publication.
FDA Disclosure: QUAD is a compounded prescription medication, not an FDA-approved finished product, under either its current or prior formula. Compounded medications are not reviewed by FDA for safety, effectiveness, or quality before marketing.
California Proposition 65: QUAD is dispensed as a compounded prescription medication through a licensed pharmacy following clinical evaluation, not sold as a direct-to-consumer retail product selected without prescriber review. No product-specific California Proposition 65 warning was identified in the materials reviewed for this article. California buyers with questions about ingredient-specific disclosures should confirm directly with the prescribing provider or dispensing pharmacy.
Geographic/Jurisdiction Notice: Availability, pricing, and prescribing practices may vary by state and are subject to applicable state telehealth and pharmacy regulations. Confirm availability in your state directly with MEDVi.
Trademark Acknowledgment: QUAD™ is used by the brand as a trademark on its official materials; no registered-mark (®) designation was confirmed in the sources reviewed for this article. All other trademarks referenced are the property of their respective owners.
SOURCE: MEDVi
View the original press release on ACCESS Newswire